Patterns of DNA mismatch repair protein expression for primary and recurrent colorectal cancer at an advanced surgical unit: A retrospective audit

Lynch syndrome is an inherited cancer syndrome associated with an increased lifetime risk of colorectal cancer (CRC) and characterized by germline mutations to one of four DNA mismatch repair (MMR) genes. Immunohistochemical (IHC) testing is used to screen for Lynch syndrome; however, despite routine completion following resection of primary CRC, it is only variably completed following resection of recurrent disease. This may be significant, as MMR protein expression can change from primary to recurrent CRC. The primary aim of this study is to investigate how MMR profiles change from primary to recurrent CRC; the secondary aim is to assess rates of MMR testing of primary and recurrent disease.

[1]  F. Sinicrope,et al.  Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Sabourin,et al.  Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers , 2022, International journal of molecular sciences.

[3]  A. Gorelik,et al.  Worldwide prevalence of Lynch syndrome in patients with colorectal cancer: Systematic review and meta-analysis. , 2022, Genetics in medicine : official journal of the American College of Medical Genetics.

[4]  Belinda L. Sun.  Current Microsatellite Instability Testing in Management of Colorectal Cancer. , 2020, Clinical colorectal cancer.

[5]  C. Gilks,et al.  Should you repeat mismatch repair testing in cases of tumour recurrence? An evaluation of repeat mismatch repair testing by the use of immunohistochemistry in recurrent tumours of the gastrointestinal and gynaecological tracts , 2020, Histopathology.

[6]  L. Robinson,et al.  Screening for Lynch Syndrome by Immunohistochemistry of Mismatch Repair Proteins: Significance of Indeterminate Result and Correlation With Mutational Studies. , 2019, Archives of pathology & laboratory medicine.

[7]  P. Ding,et al.  Comparison of mismatch repair status between primary and matched metastatic sites in patients with colorectal cancer. , 2018 .

[8]  H. Lenz,et al.  Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. , 2018, Clinical advances in hematology & oncology : H&O.

[9]  W. Frankel,et al.  Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency , 2018, Modern Pathology.

[10]  M. Sawyer,et al.  Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Møller,et al.  Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database , 2017, Gut.

[12]  W. Wu,et al.  Can Microsatellite Status of Colorectal Cancer Be Reliably Assessed after Neoadjuvant Therapy? , 2017, Clinical Cancer Research.

[13]  W. Frankel,et al.  Molecular genetics of microsatellite-unstable colorectal cancer for pathologists , 2017, Diagnostic Pathology.

[14]  Bokyung Ahn,et al.  Comparison of the Mismatch Repair System between Primary and Metastatic Colorectal Cancers Using Immunohistochemistry , 2017, Journal of pathology and translational medicine.

[15]  Aung Ko Win,et al.  Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis , 2017 .

[16]  W. Frankel,et al.  Discordant Mismatch Repair Protein Immunoreactivity in Lynch Syndrome-Associated Neoplasms:  A Recommendation for Screening Synchronous/Metachronous Neoplasms. , 2016, American journal of clinical pathology.

[17]  James Ziai,et al.  Mismatch repair deficiency testing in clinical practice , 2016, Expert review of molecular diagnostics.

[18]  W. Frankel,et al.  Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis , 2016, Familial Cancer.

[19]  P. Møller,et al.  Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database , 2015, Gut.

[20]  F. Sinicrope,et al.  Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer , 2015, Current Treatment Options in Oncology.

[21]  Y. Niv,et al.  How reliable is immunohistochemical staining for DNA mismatch repair proteins performed after neoadjuvant chemoradiation? , 2014, Human pathology.

[22]  Stephanie A Cohen,et al.  The Application of Clinical Genetics Dovepress the Genetic Basis of Lynch Syndrome and Its Implications for Clinical Practice and Risk Management , 2022 .

[23]  Aung Ko Win,et al.  Substantial unexplained variation in cancer risks for MLH1 and MSH2 mutation carriers , 2012, Human mutation.

[24]  A. Krasinskas,et al.  Challenging cases encountered in colorectal cancer screening for Lynch syndrome reveal novel findings: nucleolar MSH6 staining and impact of prior chemoradiation therapy. , 2011, Human pathology.

[25]  Laetitia Huiart,et al.  Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. , 2011, JAMA.

[26]  E. Chiorean.  DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy , 2011 .

[27]  R. Yantiss,et al.  Neoadjuvant Therapy Induces Loss of MSH6 Expression in Colorectal Carcinoma , 2010, The American journal of surgical pathology.

[28]  J. Lindebjerg,et al.  Interobserver variability in the evaluation of mismatch repair protein immunostaining. , 2010, Human pathology.

[29]  H T Lynch,et al.  Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications , 2009, Clinical genetics.

[30]  Heather Hampel,et al.  Feasibility of screening for Lynch syndrome among patients with colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Shia.  Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. , 2008, The Journal of molecular diagnostics : JMD.